Simrat Randhawa
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Simrat Randhawa
The proxy statement of Dianthus Therapeutics, Inc. /DE/ reports total compensation of $5,221,537 for Simrat Randhawa in fiscal 2025, including a base salary of $530,555. Disclosed compensation is on record for 3 fiscal years. Simrat Randhawa has spoken on 1 earnings call across 1 company, most recently for Dianthus Therapeutics, Inc. /DE/ on March 9, 2026.
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Dianthus Therapeutics, Inc. /DE/ (DNTH)
Proxy statement
CurrentStart not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Dianthus Therapeutics, Inc. /DE/
Other people whose current roles at this company are on record from its filings.
- Marino Garcia CEO, Board Member
- Alison F. Lawton Chairman
- Leon O. Moulder, Jr. Chairman, Board Member
- Ryan Savitz CFO
- Steve Mahoney CFO
- Adam Veness General Counsel
- Edward Carr Chief Accounting Officer
- Anne McGeorge Board Member
- Jonathan Violin Board Member
- Jonathan Violin, Ph.D. Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | Executive Vice President, Head of Research and Development | $530,555 | $5,221,537 |
| 2024 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | Executive Vice President, Head of Research and Development | $482,000 | $4,035,266 |
| 2023 | Dianthus Therapeutics, Inc. /DE/ (DNTH) | Chief Medical Officer | $139,495 | $338,158 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.